CR20120155A - Combinacion - Google Patents
CombinacionInfo
- Publication number
- CR20120155A CR20120155A CR20120155A CR20120155A CR20120155A CR 20120155 A CR20120155 A CR 20120155A CR 20120155 A CR20120155 A CR 20120155A CR 20120155 A CR20120155 A CR 20120155A CR 20120155 A CR20120155 A CR 20120155A
- Authority
- CR
- Costa Rica
- Prior art keywords
- phenyl
- raf
- fluoro
- dimethyl
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Una combinación novedosa que comprende el inhibidor de MEK de N-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenil-amino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido-[4,3-d]-pirimidin-1-il]-fenil}-acetamida, o una sal farmacéuticamente aceptable o un solvato de la misma, con un inhibidor de B-Raf, en particular N-{3-[5-(2-amino-4-pirimidinil)-2-(1,1-dimetil-etil)-1,3-tiazol-4-il]-2-fluoro-fenil}-2,6-difluoro-bencen-sulfonamida o una sal farmacéuticamente aceptable de la misma, composiciones farmacéuticas que la comprenden, y métodos para utilizar estas combinaciones y composiciones en el tratamiento de las condiciones en donde sea benéfica la inhibición de MEK y/o B-Raf, por ejemplo, cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25221309P | 2009-10-16 | 2009-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20120155A true CR20120155A (es) | 2012-07-05 |
Family
ID=43876568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20120155A CR20120155A (es) | 2009-10-16 | 2012-03-27 | Combinacion |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US8703781B2 (es) |
| EP (5) | EP2488033B1 (es) |
| JP (1) | JP5718929B2 (es) |
| KR (1) | KR101729116B1 (es) |
| CN (1) | CN102655753B (es) |
| AU (1) | AU2010306653B2 (es) |
| BR (1) | BR112012008854B8 (es) |
| CA (1) | CA2775803C (es) |
| CL (1) | CL2012000964A1 (es) |
| CO (1) | CO6531498A2 (es) |
| CR (1) | CR20120155A (es) |
| CY (1) | CY1122013T1 (es) |
| DK (4) | DK3560498T3 (es) |
| DO (1) | DOP2012000091A (es) |
| EA (1) | EA020589B1 (es) |
| ES (4) | ES2745479T3 (es) |
| FI (2) | FI4159217T3 (es) |
| HR (3) | HRP20191617T1 (es) |
| HU (3) | HUE067723T2 (es) |
| IL (1) | IL219073A (es) |
| LT (4) | LT2488033T (es) |
| MA (1) | MA33746B1 (es) |
| ME (1) | ME03497B (es) |
| MX (1) | MX2012004413A (es) |
| MY (1) | MY174759A (es) |
| NZ (1) | NZ598913A (es) |
| PE (1) | PE20121093A1 (es) |
| PH (1) | PH12012500742A1 (es) |
| PL (4) | PL3560498T3 (es) |
| PT (4) | PT4159217T (es) |
| RS (4) | RS63702B1 (es) |
| SI (3) | SI4397376T1 (es) |
| UA (1) | UA105064C2 (es) |
| WO (1) | WO2011047238A1 (es) |
| ZA (1) | ZA201202612B (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| MX2010014066A (es) | 2008-06-16 | 2011-06-01 | Univ Tennessee Res Foundation | Compuestos para el tratamiento del cancer. |
| US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| BR112012022801B8 (pt) * | 2010-03-09 | 2019-10-29 | Dana Farber Cancer Inst Inc | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer |
| WO2012061683A2 (en) * | 2010-11-05 | 2012-05-10 | Glaxosmithkline Llc | Methods for treating cancer |
| TWI505828B (zh) * | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| EP2791170A1 (en) | 2011-12-16 | 2014-10-22 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| RU2014122867A (ru) * | 2011-12-22 | 2016-02-20 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Способ лечения рака иммунотерапевтическим средством, специфичным в отношении MAGEA3, совместно с ингибитором BRAF и/или ингибитором MEK |
| CA2868954A1 (en) * | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| CN104582706A (zh) * | 2012-09-04 | 2015-04-29 | 葛兰素史克有限责任公司 | 辅助癌症治疗的方法 |
| WO2014066606A2 (en) * | 2012-10-25 | 2014-05-01 | Glaxosmithkline Llc | Combination |
| PL2925299T3 (pl) * | 2012-11-30 | 2018-11-30 | Novartis Ag | Nowa kompozycja farmaceutyczna |
| CN103965170A (zh) * | 2013-01-24 | 2014-08-06 | 通化济达医药有限公司 | 苯磺酰胺吡唑激酶抑制剂 |
| CN105163584B (zh) | 2013-03-05 | 2019-06-04 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
| ES2822665T3 (es) * | 2013-05-31 | 2021-05-04 | Merck Sharp & Dohme | Terapias de combinación para el cáncer |
| TN2015000444A1 (en) * | 2013-06-03 | 2017-04-06 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| WO2015003571A1 (zh) * | 2013-07-08 | 2015-01-15 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的新晶型及其制备方法 |
| WO2015059677A1 (en) * | 2013-10-26 | 2015-04-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer |
| CN103588767B (zh) * | 2013-11-20 | 2016-01-20 | 苏州明锐医药科技有限公司 | 达拉菲尼的制备方法 |
| EP3079698A1 (en) * | 2013-12-12 | 2016-10-19 | Novartis AG | Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer |
| ES2660989T3 (es) | 2013-12-28 | 2018-03-27 | Guardant Health, Inc. | Métodos y sistemas para detectar variantes genéticas |
| WO2015105822A1 (en) * | 2014-01-07 | 2015-07-16 | Glaxosmithkline Llc | Cancer treatment method |
| KR20170013891A (ko) | 2014-05-06 | 2017-02-07 | 지티엑스, 인코포레이티드 | 암 치료용 화합물 |
| KR101629184B1 (ko) | 2014-12-10 | 2016-06-13 | 현대오트론 주식회사 | Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법 |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| CA3042697A1 (en) * | 2016-11-03 | 2018-05-11 | The Regents Of The University Of Michigan | Small molecule dual inhibitors of egfr/pi3k and uses thereof |
| JP2022504905A (ja) | 2018-10-16 | 2022-01-13 | ノバルティス アーゲー | 標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷 |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| US12194024B2 (en) * | 2019-07-26 | 2025-01-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease |
| US12186393B2 (en) | 2019-08-02 | 2025-01-07 | Onehealthcompany, Inc. | Method of treating transitional cell carcinoma in a canine by administering lapatinib, wherein the carcinoma harbors a BRAF mutation |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| CN118767143A (zh) | 2019-12-12 | 2024-10-15 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20230084515A1 (en) * | 2020-02-19 | 2023-03-16 | Vanderbilt University | Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| US20240310266A1 (en) | 2021-03-18 | 2024-09-19 | Novartis Ag | Biomarkers for cancer and methods of use thereof |
| CN118647382A (zh) * | 2021-11-02 | 2024-09-13 | 维瑞斯特姆股份有限公司 | 治疗异常细胞生长的方法 |
| WO2023105286A1 (en) | 2021-12-06 | 2023-06-15 | My Personal Therapeutics Ltd | A combination treatment for cancer |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| AU1529901A (en) * | 1999-11-22 | 2001-06-04 | Smithkline Beecham Plc | Compounds |
| DE102004018198A1 (de) * | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | Sulfonamide |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| SI1761528T1 (sl) * | 2004-06-11 | 2008-06-30 | Japan Tobacco Inc | 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka |
| WO2008120004A1 (en) * | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
| CA2924436A1 (en) | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
-
2010
- 2010-10-15 HU HUE22189749A patent/HUE067723T2/hu unknown
- 2010-10-15 DK DK19174594.2T patent/DK3560498T3/da active
- 2010-10-15 BR BR112012008854A patent/BR112012008854B8/pt active IP Right Grant
- 2010-10-15 US US13/499,779 patent/US8703781B2/en active Active
- 2010-10-15 EP EP10824148.0A patent/EP2488033B1/en active Active
- 2010-10-15 PL PL19174594.2T patent/PL3560498T3/pl unknown
- 2010-10-15 EP EP24175377.1A patent/EP4397376B1/en active Active
- 2010-10-15 RS RS20220984A patent/RS63702B1/sr unknown
- 2010-10-15 LT LTEP10824148.0T patent/LT2488033T/lt unknown
- 2010-10-15 DK DK10824148.0T patent/DK2488033T3/da active
- 2010-10-15 WO PCT/US2010/052808 patent/WO2011047238A1/en not_active Ceased
- 2010-10-15 UA UAA201204675A patent/UA105064C2/uk unknown
- 2010-10-15 ME MEP-2019-236A patent/ME03497B/me unknown
- 2010-10-15 FI FIEP22189749.9T patent/FI4159217T3/fi active
- 2010-10-15 LT LTEP22189749.9T patent/LT4159217T/lt unknown
- 2010-10-15 EA EA201290149A patent/EA020589B1/ru not_active IP Right Cessation
- 2010-10-15 RS RSP20191095 patent/RS59181B1/sr unknown
- 2010-10-15 SI SI201032168T patent/SI4397376T1/sl unknown
- 2010-10-15 DK DK24175377.1T patent/DK4397376T3/da active
- 2010-10-15 PT PT221897499T patent/PT4159217T/pt unknown
- 2010-10-15 RS RS20240873A patent/RS65800B1/sr unknown
- 2010-10-15 PH PH1/2012/500742A patent/PH12012500742A1/en unknown
- 2010-10-15 ES ES10824148T patent/ES2745479T3/es active Active
- 2010-10-15 PL PL10824148T patent/PL2488033T3/pl unknown
- 2010-10-15 PT PT191745942T patent/PT3560498T/pt unknown
- 2010-10-15 EP EP22189749.9A patent/EP4159217B1/en not_active Revoked
- 2010-10-15 MX MX2012004413A patent/MX2012004413A/es active IP Right Grant
- 2010-10-15 MY MYPI2012001680A patent/MY174759A/en unknown
- 2010-10-15 HR HRP20191617 patent/HRP20191617T1/hr unknown
- 2010-10-15 PL PL22189749.9T patent/PL4159217T3/pl unknown
- 2010-10-15 RS RS20260205A patent/RS67767B1/sr unknown
- 2010-10-15 NZ NZ598913A patent/NZ598913A/xx unknown
- 2010-10-15 AU AU2010306653A patent/AU2010306653B2/en active Active
- 2010-10-15 EP EP25216764.8A patent/EP4706770A2/en active Pending
- 2010-10-15 ES ES19174594T patent/ES2930157T3/es active Active
- 2010-10-15 HR HRP20260236TT patent/HRP20260236T1/hr unknown
- 2010-10-15 SI SI201031933T patent/SI2488033T1/sl unknown
- 2010-10-15 HU HUE19174594A patent/HUE060206T2/hu unknown
- 2010-10-15 LT LTEP24175377.1T patent/LT4397376T/lt unknown
- 2010-10-15 KR KR1020127012649A patent/KR101729116B1/ko active Active
- 2010-10-15 PT PT241753771T patent/PT4397376T/pt unknown
- 2010-10-15 PE PE2012000502A patent/PE20121093A1/es active IP Right Grant
- 2010-10-15 FI FIEP24175377.1T patent/FI4397376T3/fi active
- 2010-10-15 LT LTEP19174594.2T patent/LT3560498T/lt unknown
- 2010-10-15 ES ES22189749T patent/ES2986037T3/es active Active
- 2010-10-15 PL PL24175377.1T patent/PL4397376T3/pl unknown
- 2010-10-15 EP EP19174594.2A patent/EP3560498B1/en not_active Revoked
- 2010-10-15 SI SI201032148T patent/SI4159217T1/sl unknown
- 2010-10-15 ES ES24175377T patent/ES3063926T3/es active Active
- 2010-10-15 CA CA2775803A patent/CA2775803C/en active Active
- 2010-10-15 PT PT10824148T patent/PT2488033T/pt unknown
- 2010-10-15 DK DK22189749.9T patent/DK4159217T3/da active
- 2010-10-15 JP JP2012534386A patent/JP5718929B2/ja active Active
- 2010-10-15 HR HRP20221304TT patent/HRP20221304T1/hr unknown
- 2010-10-15 CN CN201080046640.6A patent/CN102655753B/zh active Active
- 2010-10-15 HU HUE10824148A patent/HUE046139T2/hu unknown
-
2012
- 2012-03-27 CR CR20120155A patent/CR20120155A/es unknown
- 2012-04-03 DO DO2012000091A patent/DOP2012000091A/es unknown
- 2012-04-05 IL IL219073A patent/IL219073A/en active IP Right Grant
- 2012-04-11 ZA ZA2012/02612A patent/ZA201202612B/en unknown
- 2012-04-16 CL CL2012000964A patent/CL2012000964A1/es unknown
- 2012-04-27 CO CO12069732A patent/CO6531498A2/es active IP Right Grant
- 2012-05-11 MA MA34863A patent/MA33746B1/fr unknown
-
2014
- 2014-03-05 US US14/197,421 patent/US8952018B2/en active Active
- 2014-12-22 US US14/578,804 patent/US20150111904A1/en not_active Abandoned
-
2019
- 2019-09-09 CY CY20191100943T patent/CY1122013T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20120155A (es) | Combinacion | |
| PH12015502415A1 (en) | Combinations | |
| UY30298A1 (es) | Inhibidores de la quinasa c-fms ii | |
| CL2008001038A1 (es) | Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano | |
| CR9901A (es) | Combinaciones antineoplasicas con inhibidor de objetivo de rapamicina en mamiferos, herceptina, y/o hki-272 | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| CR20110339A (es) | Compuestos útiles para inhibir chk1 | |
| BR112016011222A2 (pt) | Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer | |
| CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
| CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
| CL2012000755A1 (es) | Compuestos especificos 2-(3-amino-1-(2,4-difluorofenil)-1h-1,2,4-triazol-5-il)-n-metil-4,5-dihidrobenzeno(b) tieno(2,3-d)oxepina-8-carboxamida, inhibidor de la ctividad de la quinasa p13; composicon farmaceutica que lo comprende; kit farmaceutico que incluye a la composicion, y su uso para el tratamiento o profilaxis del cancer. | |
| CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
| CL2007002494A1 (es) | Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion. | |
| AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| BR112015009134A2 (pt) | combinação | |
| CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
| PE20170469A1 (es) | Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontano que utilizan composiciones de udenafilo | |
| MX350019B (es) | Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-bencimidaz ol-4-carboxamida. | |
| AR054253A1 (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
| BR112012011677A2 (pt) | combinação, kit de combinação e uso de uma combinação | |
| CL2007000485A1 (es) | Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina. | |
| AR065077A1 (es) | Composiciones farmaceuticas y metodos para utilizar temozolomida e inhibidores de quinasa multidirigidos | |
| CL2007002525A1 (es) | Forma cristalina qalfa de maleato de (r)-5-[2-(5,6-dietil-indan-2-il-amino)-1-hidroxi-etil]-8-hidroxi-1h-quinolin-2-ona; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso para el tratamiento de una enfermedad inflamatoria | |
| ES2536842T3 (es) | Composición farmacéutica para el tratamiento del cáncer | |
| CL2008002555A1 (es) | Composicion farmaceutica que comprende un compuesto de levosimendan y un segundo ingrediente activo un antagonista del receptor de angiotensiva ii; un kit farmaceutico que comprende dicha composicion; y su uso para la prevencion o la inhibicion de apoplejia. |